Pegloticase is a powerful but underutilized weapon in the rheumatologist's armamentarium. The drug's immunogenicity leads to neutralizing antibody formation and rapid loss of efficacy in roughly one-half of all patients, which remains an impediment to broader use. New data, however, suggest that drug survival might improve with concomitant immunosuppressive agent (s), which merits further study. Efficacy appears to be unchanged when pegloticase is infused at 3-week (rather than 2-week) intervals. Stretching the time between infusions may also improve patient adherence and allow for earlier identification of transient responders. © 2014 Abeles; licensee BioMed Central Ltd.
CITATION STYLE
Abeles, A. M. (2014, May 30). PEG-ing down (and preventing?) the cause of pegloticase failure. Arthritis Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/ar4572
Mendeley helps you to discover research relevant for your work.